Recombinant new coronavirus vaccine (CHO cells) placebo group

BIOLOGICAL4 trials

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Conditions

CoronavirusPrevention of COVID-19Safety and Efficacy

Phase 1

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2020-06-22End: 2021-09-20Updated: 2020-12-03

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

CompletedNCT04961359

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2021-07-03End: 2023-04-06Updated: 2023-04-25

Phase 2

Clinical Study of Recombinant Novel Coronavirus Vaccine

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2020-07-12End: 2021-12-15Updated: 2020-12-03

Phase 3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Prevention of COVID-19, Safety and Efficacy

Start: 2020-12-16End: 2022-12-31Updated: 2022-01-19

Related Papers

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.

2023-02-1715 citations

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

New England Journal of Medicine2022-05-04248 citations

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

2021-03-24353 citations